Loading organizations...
Opaleye Management operates as a hedge fund, specializing in strategic investments within the healthcare sector. The firm primarily allocates capital to small and mid-sized companies across biotechnology, specialty pharmaceuticals, and medical devices. Its approach involves identifying and backing enterprises positioned for growth and innovation within these specialized market segments.
Founded in 1996 by James Aaron Silverman, Opaleye Management emerged from a keen insight into the specific opportunities within the evolving healthcare industry. Silverman, who serves as President and Chief Compliance Officer, established the firm to focus on the nuanced landscape of emerging healthcare ventures, dedicating his leadership to this specialized investment niche.
The fund primarily serves investors seeking exposure to the growth potential within healthcare innovation. Opaleye Management’s vision centers on fostering advancements in medicine and patient care through its investment activities. The firm aims to be a significant financial partner for healthcare companies, thereby supporting the broader ecosystem of medical progress.
Opaleye Management has 4 tracked investments across 4 companies. The latest tracked deal is $10.0M Seed in IpiNovyx Bio in October 2021.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Oct 1, 2021 | IpiNovyx Bio | $10.0M Seed | — | AD Astra Ventures, Leawood Venture Capital, Alexandria Venture Investments, ELI Lilly And Company, Marc Spencer Appel |
| Apr 1, 2021 | Tesseract Health | $80.0M Series B | — | ARCH Venture Partners, Foresite Capital, Krishna Yeshwant, Vzvc, Larry Robbins |
| May 1, 2020 | Palvella Therapeutics | $45.0M Series C | — | Samsara BioCapital, Adams Street Partners, Agent Capital, BioAdvance, BVF Partners, Scott Morenstein, Ligand Pharmaceuticals, Sean Nolan |
| Jun 20, 2019 | Acutus Medical | $170.0M Debt / Series D | — | Vince Burgess, Advent Venture Partners, Deerfield Management, GE Ventures, OrbiMed, Pura Vida Investments, Xeraya Capital |